Compare IDEXX Laboratories, Inc. (IDXX) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nokia Corp — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while Nokia Corp trades at $10.65 (market cap $56.70B). The key difference: Nokia Corp is the larger of the two by market cap, and Nokia Corp pays a 1.63% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NOK | |
|---|---|---|
Market Cap | $44.48B | $56.70B |
Sector | Health | Technology |
52-Week High | $766.68 | $16.83 |
52-Week Low | $520.87 | $4.05 |
Enterprise Value | $45.38B | $53.51B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Nokia (NOK) trades at $10.115, down 0.05% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates, but has beaten expectations in prior quarters. Revenue for 2025 was $19.89B with a net income margin of 3.98%, while the P/E ratio stands at 63.48, indicating a premium valuation. Recent news highlights Nokia's strategic pivot to AI-powered networking, including partnerships with Nvidia and telecom providers.
The outlook for NOK is cautiously optimistic, driven by AI and 5G demand, but high valuation and recent earnings miss pose risks. Analyst consensus is a Buy with a $18.00 price target, suggesting significant upside. Key risks include execution on AI initiatives, competitive pressures, and supply chain constraints. The stock's performance hinges on delivering sustained growth from its AI infrastructure investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
